FOLFOX-HAIC

PROCEDURE3 trials

Sponsors

Sun Yat-sen University, Henan Cancer Hospital

Conditions

HCC - Hepatocellular CarcinomaHepatocellular CarcinomaHepatocellular Carcinoma (HCC)

Phase 3

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Active, not recruitingNCT05198609

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2022-01-17End: 2026-07-01Target: 214Updated: 2026-01-21

Unknown Phase

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

CompletedNCT07272265

Sun Yat-sen UniversityHepatocellular Carcinoma (HCC)

Start: 2020-10-28End: 2025-11-10Updated: 2025-12-09

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Not yet recruitingNCT07618546

Henan Cancer HospitalHCC - Hepatocellular Carcinoma

Start: 2026-05-25End: 2028-03-31Target: 208Updated: 2026-06-01

Related Papers

Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial.

Journal of Clinical Oncology2024-06-012 citations